RCM
KRTX

Riverhead Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Riverhead Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$10K Hold
642
– – ﹤0.01% 1490
2019
Q2 		$10K Buy
+642
New +$12.9K ﹤0.01% 1509

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Riverhead Capital Management's KRTX Position: Q3 2019 in Review

Riverhead Capital Management held its Karuna Therapeutics, Inc. Common Stock (KRTX) position steady in Q3 2019 at 642 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1490.

Riverhead Capital Management first reported a position in KRTX in Q2 2019 and has held it in 2 quarters since. 50 funds tracked by Wall St. Rank hold KRTX as of Q3 2019.

  • Riverhead Capital Management held 642 shares of Karuna Therapeutics, Inc. Common Stock worth $10K as of Q3 2019.
  • Riverhead Capital Management left its Karuna Therapeutics, Inc. Common Stock share count unchanged in Q3 2019.
  • Karuna Therapeutics, Inc. Common Stock made up ﹤0.01% of Riverhead Capital Management's portfolio in Q3 2019, its #1490 holding.
  • Riverhead Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and has held it in 2 quarters since.
  • 50 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.